I'm LongbridgeAI, I can summarize articles.BIOMERICA INC reported Q1 FY2027 results with revenue of $1.265M, down 8.3% YoY due to lower clinical lab orders, and a net loss of $(1.232M). Diluted EPS was $(0.37). Business highlights include increased OTC sales, Medicare rollout for inFoods®, FDA clearance for hp+detect™, a $1.75M CDM services agreement, and a $2.23M private placement.
BIOMERICA INC reported first-quarter fiscal 2027 results, with revenue of $1.265M, a net loss of $(1.232M) attributable to shareholders and diluted EPS of $(0.37), compared with revenue of $1.38M and a small net income in the year‑ago quarter — 10-Q Summary.
Financial Highlights
- Revenue was $1.265M for Q1 FY2027 (three months ended Aug 31, 2026), compared with $1.380M in the prior-year quarter; YoY change (8.3%).
- Net income was a loss of $(1.232M) attributable to shareholders for Q1 FY2027, versus $2.0K net income in the year‑ago quarter.
- Diluted EPS was $(0.37) for Q1 FY2027, compared with $0.00 in the year‑ago quarter.
Business Highlights
- Revenue mix shifted as lower clinical lab orders drove the 8% YoY decline, while OTC sales increased and contract manufacturing remained steady.
- Commercial rollout of inFoods® IBS advanced with Medicare payment rate established and initial Medicare orders showing month‑over‑month growth.
- hp+detect™ secured FDA 510(k) clearance and UK MHRA registration, with initial commercial orders and reorders in Europe.
- Signed a target master services agreement exceeding $1.75M for CDM services to leverage existing FDA/ISO‑certified manufacturing capacity.
- Completed a $2.23M private placement to support commercialization, reimbursements, and to scale sales and marketing efforts.
Original SEC Filing: BIOMERICA INC [ BMRA ] - 10-Q - Oct. 15, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.